Table 4 Protein classification of the potential SCZ drug targets
From: A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case
Protein class | Protein | Potential SCZ drugs with clinical trials | |
|---|---|---|---|
Receptor | ADRA1A | Trazodone | Â |
| Â | CHRM1 | Benztropine | Desipramine |
| Â | DRD1 | Pergolide | Dopamine |
| Â | DRD2 | Bromocriptine | Pergolide |
| Â | Â | Pramipexole | Dopamine |
| Â | Â | Buspirone | Levodopa |
| Â | DRD3 | Bromocriptine | Pergolide |
| Â | Â | Pramipexole | Dopamine |
| Â | DRD4 | Pramipexole | Levodopa |
| Â | Â | Dopamine | Â |
| Â | DRD5 | Dopamine | Â |
| Â | HRH1 | Betahistine | Cinnarizine |
| Â | Â | Cyproheptadine | Desipramine |
| Â | Â | Promethazine | Mirtazapine |
| Â | HRH2 | Famotidine | Nizatidine |
| Â | HTR1A | Naratriptan | Buspirone |
| Â | HTR1B | Naratriptan | Â |
| Â | HTR1D | Naratriptan | Â |
| Â | HTR2A | Mirtazapine | Zotepine |
| Â | Â | Trazodone | Â |
| Â | HTR2C | Agomelatine | Mirtazapine |
Transporter | SLC6A2 | Atomoxetine | Desipramine |
| Â | Â | Methamphetamine | Reboxetine |
| Â | Â | Methylphenidate | Sibutramine |
| Â | SLC6A3 | Dexmethylphenidate | Methylphenidate |
| Â | SLC6A4 | Citalopram | Fluoxetine |
| Â | Â | Fluvoxamine | Paroxetine |
| Â | Â | Methamphetamine | Sertraline |
| Â | Â | Sibutramine | Trazodone |
Transporter; | GABRA1 | Lorazepam | Diazepam |
Receptor | Â | Nitrazepam | Zolpidem |
| Â | GABRG2 | Lorazepam | Diazepam |
| Â | GRIN2B | Memantine | Â |
| Â | HTR3A | Ondansetron | Mirtazapine |
(Not available) | ADRA2A | Dexmedetomidine | Clonidine |
| Â | Â | Mirtazapine | Guanfacine |
| Â | ADRA2B | Clonidine | Â |
| Â | ADRA2C | Dexmedetomidine | Clonidine |